ArticleInternational journal of clinical pharmacy2019
The use of nephrotoxic drugs in patients with chronic kidney disease.
Article in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors.Renal failure · 2026Observational
- Usnic acid attenuates inflammation and joint damage in Freund's complete adjuvant-induced arthritis in rats.Inflammopharmacology · 2026Article
- Sambucus nigra alleviates fenpropathrin-induced hepatorenal toxicity in rats via modulation of NF-κB/TNF-α axis.Scientific reports · 2025Article
- Ten-Year Trend in the Potentially Inappropriate Prescribing of Renally-Dependent Medicines in Australian General Practice Patients with Dementia.Journal of clinical medicine · 2025Article
- Assessment of Potentially Nephrotoxic Drug Prescriptions in Chronic Kidney Disease Outpatients at a Hospital in Indonesia.International journal of nephrology and renovascular disease · 2025Article
- Predicting dietary management intention of patients with chronic kidney disease using protection motivation theory.PloS one · 2025Article
- Magnitude of multiple drug use and determinants of vulnerability among chronic kidney disease inpatients in Ethiopia: a multi-center study.BMC nephrology · 2024Article
- Hematological changes, oxidative stress assessment, and dysregulation of aquaporin-3 channel, prolactin, and oxytocin receptors in kidneys of lactating Wistar rats treated with monosodium glutamate.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Association between polypharmacy and chronic kidney disease among community-dwelling older people: a longitudinal study in southern China.BMC nephrology · 2024Article
- Protective role of citronellol on antioxidant enzymes and oxidative damage induced by gentamicin in experimental nephrotoxic rats.Molecular biology reports · 2024Article
- Nephrotoxic drug burden and predictors of exposure among patients with renal impairment in Ethiopia: A multi-center study.Heliyon · 2024Article
- Review
- Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study.BMC primary care · 2022Observational
- Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care.Clinical kidney journal · 2022Article
- Investigation of potential descriptors of chemical compounds on prevention of nephrotoxicity via QSAR approach.Computational and structural biotechnology journal · 2022Article
- A focus on CKD reporting and inappropriate prescribing among older patients discharged from geriatric and nephrology units throughout Italy: A nationwide multicenter retrospective cross-sectional study.Frontiers in pharmacology · 2022Article
- Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients.Frontiers in pharmacology · 2021Article
- Kidney Disease Knowledge and Its Determinants Among Patients With Chronic Kidney Disease.Journal of patient experience · 2020Article
- Chronic Kidney Disease Management in General Practice: A Focus on Inappropriate Drugs Prescriptions.Journal of clinical medicine · 2020Article
- Lack of knowledge about chronic kidney disease and its consequences.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The use of nephrotoxic drugs has the potential to accelerate the loss of kidney function and increase the risk of end-stage renal disease. Objectives To determine the prevalence of nephrotoxic drugs use in patients with chronic kidney disease at two major hospitals in Maiduguri and to evaluate the predictors of exposure to the contraindicated ones. Methods This retrospective study used data from the patients' medical records. Patients aged ≥ 18 years that were diagnosed with chronic kidney disease from 2013 to 2017 with documented serum creatinine levels for the period under review were included in the study. Descriptive statistics were used to summarize the socio-demographics, clinical and biochemical characteristics of the study population. Predictors of nephrotoxic, and contraindicated nephrotoxic medication exposure were assessed using Chi square and logistic regression tests respectively. Results The results are based on data from 201 patients. Of these, 96.0% received at least one prescription of a nephrotoxic drug within the period under review. Multivariate logistic regression showed that the odds of receiving the seven contraindicated nephrotoxic drugs increased in those aged 60 years or older (OR 8.00, 95% CI 1.67-38.40), and those with mild/moderate chronic kidney disease (OR 3.51, 95% CI 1.14-10.77). Main Outcome Measure Prevalence of nephrotoxic drug exposure in patients with chronic kidney disease. Conclusions Large proportions of patients with chronic kidney disease received nephrotoxic drugs, mainly diuretics. However, patients aged 60 years or older, and those at chronic kidney disease stages 2-3 were significantly more likely to receive contraindicated nephrotoxic drugs compared to other age groups and chronic kidney disease stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.